Application-Assisted Weight Management in Endometrial Cancer Fertility Preservation

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Mar 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a special mobile application can help women with endometrial cancer who are trying to manage their weight while preserving their fertility. The research is being conducted at Peking University People's Hospital from March 2025 to March 2027. The goal is to see if using this app can lead to better weight management, improvements in body mass index (BMI), and even help shrink tumors and improve how the body processes sugar and fats.

To be eligible for this trial, participants need to be women aged 18 to 74 with a BMI of 25 or higher, meaning they are considered overweight or obese. They must have a confirmed diagnosis of early-stage endometrial cancer and be actively looking to preserve their fertility. Participants will be required to use the app and follow its guidance while receiving fertility-preserving treatment. It's important to note that individuals with certain severe health conditions or those currently using weight-loss medications will not be eligible. This trial offers a unique opportunity for qualified women to manage their weight effectively during a challenging time.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • BMI ≥ 25 kg/m²
• • Histologically confirmed endometrial carcinoma via diagnostic curettage, hysteroscopic endometrial biopsy, or needle biopsy
• • Clinical FIGO 2009 stage IA disease: No evidence of extrauterine metastasis or myometrial invasion on imaging (MRI/CT)
• • ECOG \< 2
• • Active desire to preserve fertility
• • Fertility-preserving treatment
• • Willingness to participate and signed informed consent
• Exclusion Criteria:
• • High-grade or p53-mutated (p53mut) endometrial cancer
• • Currently using weight-loss medications
• • Pregnant or breastfeeding
• • Presence of communication barriers that prevent understanding and participation in the informed consent process
• • Participation in other weight-loss programs
• • Inability to safely engage in unsupervised physical activities
• • Undergoing anticoagulant therapy that may affect body composition, weight, or energy expenditure
• • Severe comorbidities: urinary system stones, history of renal failure or severe renal insufficiency, familial dyslipidemia, severe liver disease, chronic metabolic acidosis, history of pancreatitis, severe diabetes, active gallbladder disease, fat malabsorption, severe cardiovascular and cerebrovascular diseases
• • Presence of unstable medical conditions: uncontrolled hypertension, diabetes, unstable angina, transient ischemic attack, other cancers currently under treatment, Crohn's disease